×
S&P 500   3,825.33 (+1.06%)
DOW   31,097.26 (+1.05%)
QQQ   282.01 (+0.62%)
AAPL   138.95 (+1.63%)
MSFT   259.63 (+1.09%)
META   160.05 (-0.74%)
GOOGL   2,173.25 (-0.28%)
AMZN   109.50 (+3.10%)
TSLA   679.75 (+0.94%)
NVDA   144.90 (-4.41%)
NIO   21.37 (-1.61%)
BABA   115.95 (+2.00%)
AMD   73.54 (-3.83%)
MU   53.65 (-2.95%)
CGC   2.80 (-1.75%)
T   21.32 (+1.72%)
GE   63.54 (-0.20%)
F   11.32 (+1.71%)
DIS   96.18 (+1.89%)
AMC   13.47 (-0.59%)
PFE   52.32 (-0.21%)
PYPL   70.74 (+1.29%)
NFLX   180.10 (+2.99%)
S&P 500   3,825.33 (+1.06%)
DOW   31,097.26 (+1.05%)
QQQ   282.01 (+0.62%)
AAPL   138.95 (+1.63%)
MSFT   259.63 (+1.09%)
META   160.05 (-0.74%)
GOOGL   2,173.25 (-0.28%)
AMZN   109.50 (+3.10%)
TSLA   679.75 (+0.94%)
NVDA   144.90 (-4.41%)
NIO   21.37 (-1.61%)
BABA   115.95 (+2.00%)
AMD   73.54 (-3.83%)
MU   53.65 (-2.95%)
CGC   2.80 (-1.75%)
T   21.32 (+1.72%)
GE   63.54 (-0.20%)
F   11.32 (+1.71%)
DIS   96.18 (+1.89%)
AMC   13.47 (-0.59%)
PFE   52.32 (-0.21%)
PYPL   70.74 (+1.29%)
NFLX   180.10 (+2.99%)
S&P 500   3,825.33 (+1.06%)
DOW   31,097.26 (+1.05%)
QQQ   282.01 (+0.62%)
AAPL   138.95 (+1.63%)
MSFT   259.63 (+1.09%)
META   160.05 (-0.74%)
GOOGL   2,173.25 (-0.28%)
AMZN   109.50 (+3.10%)
TSLA   679.75 (+0.94%)
NVDA   144.90 (-4.41%)
NIO   21.37 (-1.61%)
BABA   115.95 (+2.00%)
AMD   73.54 (-3.83%)
MU   53.65 (-2.95%)
CGC   2.80 (-1.75%)
T   21.32 (+1.72%)
GE   63.54 (-0.20%)
F   11.32 (+1.71%)
DIS   96.18 (+1.89%)
AMC   13.47 (-0.59%)
PFE   52.32 (-0.21%)
PYPL   70.74 (+1.29%)
NFLX   180.10 (+2.99%)
S&P 500   3,825.33 (+1.06%)
DOW   31,097.26 (+1.05%)
QQQ   282.01 (+0.62%)
AAPL   138.95 (+1.63%)
MSFT   259.63 (+1.09%)
META   160.05 (-0.74%)
GOOGL   2,173.25 (-0.28%)
AMZN   109.50 (+3.10%)
TSLA   679.75 (+0.94%)
NVDA   144.90 (-4.41%)
NIO   21.37 (-1.61%)
BABA   115.95 (+2.00%)
AMD   73.54 (-3.83%)
MU   53.65 (-2.95%)
CGC   2.80 (-1.75%)
T   21.32 (+1.72%)
GE   63.54 (-0.20%)
F   11.32 (+1.71%)
DIS   96.18 (+1.89%)
AMC   13.47 (-0.59%)
PFE   52.32 (-0.21%)
PYPL   70.74 (+1.29%)
NFLX   180.10 (+2.99%)
NASDAQ:CLBS

Caladrius Biosciences Price Target, Predictions & Analyst Ratings

$0.53
0.00 (-0.57%)
(As of 07/1/2022 03:58 PM ET)
Add
Compare
Today's Range
$0.50
$0.53
50-Day Range
$0.41
$0.64
52-Week Range
$0.40
$1.64
Volume
4,247 shs
Average Volume
469,349 shs
Market Capitalization
$31.89 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

Caladrius Biosciences (NASDAQ:CLBS) Price Target and Consensus Rating (2022)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Buy
Based on 1 Analyst Ratings

Consensus Analyst Price Target

$6.00
1,038.52% Upside
High Price Target$6.00
Average Price Target$6.00
Low Price Target$6.00
TypeCurrent
7/1/21 to 7/1/22
1 Month Ago
6/1/21 to 6/1/22
3 Months Ago
4/2/21 to 4/2/22
1 Year Ago
7/1/20 to 7/1/21
Consensus Rating
Buy
Buy
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
2 Buy rating(s)
2 Buy rating(s)
2 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$6.00$6.00$6.00$12.00
Predicted Upside1,038.52% Upside710.81% Upside710.81% Upside571.64% Upside
Get Caladrius Biosciences Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for CLBS and its competitors with MarketBeat's FREE daily newsletter.


CLBS Stock Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CLBS Stock Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Caladrius Biosciences Stock vs. The Competition

TypeCaladrius BiosciencesMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.71
2.51
Consensus RatingBuyBuyBuy
Predicted Upside1,100.00% Upside453.36% Upside33.61% Upside
News Sentiment RatingPositive News
Positive News
Neutral News
MarketBeat
Community Rating
Outperform Votes
324
66.80%
Underperform Votes
161
33.20%
Avg. Outperform Votes
170
66.93%
Avg. Underperform Votes
84
33.07%
Avg. Outperform Votes
840
69.14%
Avg. Underperform Votes
375
30.86%

Historical Caladrius Biosciences Price Targets and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
3/23/2022HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$8.00 ➝ $6.00+710.80%
6/22/2021Brookline Capital Management
Subscribe to MarketBeat All Access for the recommendation accuracy rating
K. Raja
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy
5/18/2020Dawson James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Kolbert
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral
5/15/2020Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy$6.00+252.94%
(Data available from 7/1/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)












Caladrius Biosciences Price Target - Frequently Asked Questions

What is Caladrius Biosciences's consensus rating and price target?

According to the issued ratings of 1 analysts in the last year, the consensus rating for Caladrius Biosciences stock is Buy based on the current 1 buy rating for CLBS. The average twelve-month price prediction for Caladrius Biosciences is $6.00 with a high price target of $6.00 and a low price target of $6.00. Learn more on CLBS's analyst rating history.

Do Wall Street analysts like Caladrius Biosciences more than its competitors?

Analysts like Caladrius Biosciences stock more than the stock of other Medical companies. The consensus rating score for Caladrius Biosciences is 3.00 while the average consensus rating score for medical companies is 2.71. Learn more on how CLBS compares to other companies.

Do MarketBeat users like Caladrius Biosciences more than its competitors?

MarketBeat users like Caladrius Biosciences stock less than the stock of other Medical companies. 66.80% of MarketBeat users gave Caladrius Biosciences an outperform vote while medical companies recieve an average of 66.93% outperform votes by MarketBeat users.

Does Caladrius Biosciences's stock price have much upside?

According to analysts, Caladrius Biosciences's stock has a predicted upside of 710.81% based on their 12-month price targets.

This page (NASDAQ:CLBS) was last updated on 7/1/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.